GLP‑1s are reshaping industries

Weight-loss drugs are starting to show up in places that have nothing to do with pharmacies: clothing racks, filler clinics, protein aisles, and gym sales desks. Business Insider reported on April 11 that fashion, plastic surgery, fitness, and supplements are among the businesses getting a lift from the boom in glucagon-like peptide-1 drugs. (businessinsider.com) These drugs were built for medicine, not retail. Wegovy, made by Novo Nordisk, is approved by the Food and Drug Administration for long-term weight management in adults with obesity, and Zepbound, made by Eli Lilly, is approved for the same basic use alongside diet and exercise. (accessdata.fda.gov 1) (accessdata.fda.gov 2) The scale is big enough to move whole categories. Kaiser Family Foundation found in May 2024 that 12% of U.S. adults had ever taken a glucagon-like peptide-1 drug and 6% were taking one at that moment, and newer 2025 survey reporting cited by eMarketer put current use at 12% of adults. (kff.org) (emarketer.com) Drugmakers are seeing that surge in their own numbers. Novo Nordisk said its obesity portfolio grew 31% in 2025 and reached 3.6 million people worldwide, while Eli Lilly’s 2025 results were driven by fast growth from Mounjaro and Zepbound. (annualreport.novonordisk.com) (stocklight.com) Apparel is the easiest place to see the spillover. CNBC reported on April 9 that Bernstein estimates glucagon-like peptide-1 drugs could add as much as $13 billion a year to clothing spending as people replace wardrobes while their sizes change. (cnbc.com) That does not just mean people buying smaller jeans once. CNBC reported in September 2025 that retailers were seeing more demand for smaller sizes and faster turnover because customers were moving through several sizes instead of staying in one fit for years. (cnbc.com) Plastic surgery clinics are getting a different kind of demand. A 2025 systematic review in Aesthetic Surgery Journal Open Forum said the term “Ozempic face” had been coined for facial volume loss after semaglutide-related weight loss, which helps explain why fillers, fat grafting, and skin-tightening treatments are being marketed to this group. (academic.oup.com) Gyms are not being replaced by the drugs; they are trying to sell around them. Inspire360’s March 2026 report tracked 17 health club chains and 10 solution providers taking concrete action in the glucagon-like peptide-1 market, including partnerships, prescribing programs, and training plans built around members using the drugs. (inspire360.com) The pitch from gyms is tied to a real physical problem. Health.com reported on April 11 that muscle loss is common on glucagon-like peptide-1 medications, and strength training is one of the main ways users are told to protect muscle while body weight falls. (health.com) Supplement companies are chasing the same gap from the nutrition side. Today reported on April 11 that a new study found glucagon-like peptide-1 users were getting critically low protein intake and skipping meals, which creates a ready-made market for protein shakes, fiber products, and electrolyte mixes. (today.com) Trade shows are already filling up with products aimed at that customer. Nutritional Outlook reported in December 2025 that “GLP-1 support” was the most prominent trend at SupplySide Global 2025, with ingredient makers pitching products for people using the drugs and products meant to mimic some of the same appetite effects. (nutritionaloutlook.com) That is why this story is spreading far beyond two drug companies. PricewaterhouseCoopers said the biology of glucagon-like peptide-1 drugs is now cascading into food, wellness, beauty, retail, and travel, which means a prescription that starts in a doctor’s office is starting to rewire shopping lists and service businesses across the economy. (pwc.com)